At 1 year, the cumulative risk of amputation 18% was identical in the two groups, while the cumula tive survival rate was significantly improved in patients randomized to the thrombolysis group 84% vs 58% at 12 months, p. Low dose streptokinase in treatment of arterial occlusions. Acute limb ischemia is defined as a quickly developing or sudden decrease in limb perfusion, usually producing new or worsening symptoms or signs, and often threatening limb viability. The principal active ingredient of kinlytic is the low molecular weight form of urokinase, and consists of an a chain of 2,000 daltons linked by a sulfhydryl bond to a b chain of 30,400 daltons.
Endovascular treatment options of acute limb ischemia. Thrombotic occlusion is the most common cause of acute limb ischemia. Acute ischaemia, upper limb, thrombolytic therapy, amputation. Effects of intravenous and catheter directed thrombolytic therapy with recombinant tissue plasminogen activator alteplase in nontraumatic acute limb ischemia.
Stage description findings arterial doppler signal. Fortyeight studies 22 urokinase, 22 rtpa, and 4 that included both treatments were identified, encompassing 2226 urokinasetreated patients and 1927 rtpatreated patients. Article information, pdf download for thrombolysis in peripheral artery disease. To evaluate the combination of a platelet glycoprotein iibiiia complex receptor inhibitor and urokinase for treatment of recent. Acute limb ischaemia poses a threat to both the limb and life of a patient. Intraarterial thrombolysis for acute limb ischemia. Acute limb ischemia ali is a surgical emergency with potentially limb and lifethreatening complications. Quality improvement guidelines for percutaneous catheterdirected intraarterial thrombolysis and mechanical thrombectomy for acute lowerlimb ischemia. Effective and comprehensive management of acute limb ischemia is vital. Acute limb ischemia ali occurs when there is a sudden halt of blood flow to the arm or leg, mostly owing to thrombosis or emboli. All patients receiving urokinase infusions at our institution currently require a bed in the highdependency unit hdu.
Thrombolytic techniques afford an alternative method of management for this condition and are effective in selected patients. Isolated limb perfusion with urokinase over a 90minute period was used in the treatment of a 69yearold female patient with acute ischemia of the left leg after thrombosis of a femoral artery bypass graft. For patients with chronic limb ischemia 14 days, irreversible acute limb ischemia, or advanced diabetic arteriopathy, catheterdirected infusion of rtpa or other plasminogen activators may be unsuitable. Its halflife is 47 min, and the recommended dose is 0. Case reports illustrating the application of expert. Article pdf available in european journal of vascular and endovascular surgery 592 december 2019 with 253. A sudden decrease in limb perfusion that threatens limb viability defines acute limb ischemia ali and represents a major vascular emergency. Thrombolysis for acute arterial occlusion journal of vascular surgery. Isolated limb perfusion with urokinase was used to salvage an acutely ischemic lower limb.
Acute lower extremity ischemia is overwhelmingly related to arterial occlusion, though extensive venous occlusion can lead to extremity ischemia as well ie, phlegmasia, but this. It occurs much more often in the lower than in the upper extremities. The average duration of symptoms in the patients with a graft thrombosis was 10 days range, 160 days. Effect of systemic urokinase infusion after lower limb. Thrombolytic therapy in the management of acute limb. Intracarotid urokinase with thromboembolic occlusion of. The activity of urokinase leads to a dosedependent decrease in. Thrombolysis in acute lower limb ischemia annals of vascular. Acute limb ischaemia is defined as the sudden decrease in limb perfusion that threatens the viability of the limb. Urokinase is a thrombolytic thrombolitik drug, sometimes called a clotbusting drug. Kmj endovascular treatment of acute limb ischemia due to. In this article, we shall look at the causes, clinical features and management of a patient with acute limb ischaemia. Intraarterial urokinase for acute native arterial occlusion of the limbs. Small fractions of the administered dose are excreted in bile and urine.
We investigated any correlation between ia doses of uk or rt and safety outcomes in patients who underwent et. Thrombolysis in peripheral artery disease sotirios giannakakis. The treatment options for this lifethreatening condition are open surgery, percutaneous endovascular treatment, and intravenous i. In contrast, endogenous fibrinolysis, using onethousandth of the tpa concentration, is regularly lysing fibrin and induced thrombolysis in myocardial infarction flow grade 3 patency in 15% of patients with. Antithrombotic therapy and prevention of thrombosis, 9th. Complete or even partial occlusion of the arterial supply to a limb can lead to rapid ischaemia and poor functional outcomes within hours.
Powder for solution for injection or infusion including dosage instructions and possible side effects. Acute limb ischemia ali is a serious condition requiring prompt intervention due to a sudden decrease in limb perfusion threatening limb viability. Acute less than 14 day duration of a previously patent bypass graft or native artery acute arterial embolus not accessible to embolectomy acute thrombosis of a popliteal artery aneurysm resulting in severe ischemia, provided that all runoff vessels are also thrombosis acute thromboemboli occlusion in. Acute limb ischemia ali is a rapid decrease in lower limb blood flow due to acute occlusion of peripheral artery or bypass graft, and in ali not only limbs but also life prognosis will be. A comprehensive spectrum of ali etiology is presented, with highlights on embolism and in situ thrombosis. Isolated limb perfusion with urokinase for acute ischemia.
Enhanced angiogenesis and growth of collaterals by in vivo administration of recombinant basic fibroblast growth factor in a rabbit model of acute lower limb ischemia. Current options in the diagnosis and management of acute limb. Thrombolytic therapy in the management of acute limb ischaemia. When approaching a patient with acute lower limb ischemia in the. Acute limb ischaemia is defined as the sudden decrease in limb perfusion that threatens the viability of the limb complete or even partial occlusion of the arterial supply to a limb can lead to rapid ischaemia and poor functional outcomes within hours. The clinical presentation is considered to be acute if it occurs within 14 days after symptom onset 2, 3. Fischer jr 1985 thrombolysis of peripheral arterial and graft occlusions. To evaluate the safety and effectiveness of catheterdirected thrombolysis therapy with lowdose urokinase for acute lower extremity ischemia limb. Subjects and methods the study group consisted of 22 patients with acute thromboembolic occlusion of the mca or its major branches in whom intracarotid urokinase infusion was performed between july 1984 and june 1987. Catheterdirected thrombolytic therapy in peripheral. A french multidisciplinary expert panel met to discuss the place of thrombolysis for the treatment of peripheral arterial thrombosis in the modern setting. Safety of high doses of urokinase and reteplase for acute. Request pdf endovascular treatment of acute limb ischemia and proximal deep vein thrombosis using rotational thrombectomy.
The length of the occlusions varied tables 2 and 3. The incidence of acute limb occlusion is approximately 1. The remaining 10 patients 31% had class i limb ischemia. Therapeutic angiogenesis induced by human recombinant. The safety of each thrombolytic agent was assessed based on the incidence of major hemorrhage, intracerebral hemorrhage, major limb amputation, transfusions, and mortality. Introduction thrombolytic therapy has been an established and effective treatment for acute limb ischemia for years. It helps your body produce a substance that dissolves unwanted blood clots urokinase is used to treat blood clots in the lungs urokinase may also be used for purposes not listed in this medication guide. Until recently, attempted revascularization by thrombo. Kinlytic urokinase for injection is a thrombolytic agent obtained from human neonatal kidney cells grown in tissue culture. One study compared the application of rtpa iv with ia table vii. The steps for emergency diagnosis are described, emphasizing the role of clinical data and imaging, mainly duplex ultrasound. Although the pharmacokinetics of exogenously administered urokinase have. Acute limb ischaemia ali is commonly managed with surgical intervention but catheterdirected thrombolysis cdt is a proven treatment alternative. Thrombolytic therapy with use of alteplase rtpa in.
Acute limb ischemia ali, defined as any sudden decrease in, or. Limited data exist on the safety of ia high doses of uk and rt for et. Catheterdirected thrombolysis for acute limb ischaemia. Previous balloon embolectomy and heparin therapy had failed. In some studies, lowdose systemic urokinase uk was used alone, without any intervention in patients with diabetes in order to. Quality improvement guidelines for percutaneous catheter. Cdt as a treatment for ali is not common and is dependent on local practice. Using this transthrombus technique with highdose urokinase on 49 patients it was possible. Urokinase cleavage of the argininevaline bond in plasminogen leading in active plasmin 720 min natural streptokinase. To test if initial highdose, pulsespray thrombolysis improves the early and late outcome of lower limb. Therapeutic fibrinolysis has been dominated by the experience with tissuetype plasminogen activator tpa, which proved little better than streptokinase in acute myocardial infarction. Et is considered in selected patients with ais with persistent arterial occlusion after receiving ivt. Early restoration of flow can be obtained by various treatment methods that include catheterdirected thrombolysis cdt and percutaneous mechanical thrombectomy pmt.
Acute leg ischemia is one of the most challenging and dangerous conditions in vascular surgical practice. Urokinase is used to treat blood clots in the lungs. Written while on clinical rotation at huntsville al hospital. Catheterdirected thrombolysis for acute limb ischemia. An unusual complication of pagets disease of bone article pdf available in the journal of cardiovascular surgery 402. Endovascular treatment of acute limb ischemia and proximal. If fibrinogen levels fall below 120150 mgdl the dose of tpa is decreased. When left untreated, it can threaten the viability of the limb, followed by infection, necrosis, limb loss and ultimately, death. In patients with acute limb ischemia due to acute thrombosis or embolism, we recommend surgery over peripheral arterial thrombolysis grade 1b. A total of 57 patients underwent thrombolysis with urokinase and 57. Urokinase may also be used for purposes not listed in this medication guide. Choosing the correct therapeutic option for acute limb.
Since 1988, 49 limbs of 47 patients underwent intraarterial urokinase infusion for acute native artery occlusion. Acute limb ischemia acute limb ischemia is a sudden decrease in limb perfusion that threatens limb viability and requires urgent evaluation and management. Pdf european society for vascular surgery esvs 2020 clinical. The typical dose of urokinase is 2000unitsminute 120,000unitshour. The total urokinase dose necessary for successful thrombolysis was also significantly less in the highdose group p less than.
Causes of acute limb ischemia include acute thrombosis of a limb artery or bypass graft, embolism from the heart or a diseased artery, dissection, and trauma. Most of these patients 1832 56% had class iia limb ischemia, and four patients % had class iib limb ischemia. This form of critical limb ischemia may be the first manifestation of vascular disease in a previously asymptomatic patient or occur as an acute event causing symptomatic deterioration in a patient with antecedent intermittent claudication. Acute arterial occlusion the operation was a success but the patient died high morbidity and mortality emergent operations in high risk patients 20% mortality reported dale, jvs 1984 endovascular approaches may lower periprocedural mortality while preserving outcomes. It helps your body produce a substance that dissolves unwanted blood clots. Guidelines on the management of acute limb ischaemia. Acute limb ischemia arises when a rapid or sudden decrease in limb perfusion threatens tissue viability. Acute limb ischemia is a potentially lifethreatening clinical event. New techniques lower limb intraarterial thrombolysis. These treatments have been shown to be effective but associated with various complications. The initial diagnosis of acute limb ischemia caused by a thrombosis in the popliteal artery related to a complicated. By sherelia duncan, pharmd candidate harrison school of pharmacy auburn al university. The risk of adverse bleeding appears related to the overall dose and duration of infusion. Treatment of ali depends on the clinical status of the affected limb and patient comorbidities.
Using this trans thrombus technique with highdose urokinase on 49 patients it was possible to. Read coadministration of lowdose urokinase and abciximab in thrombolysis for lower limb ischemia, thrombosis research on deepdyve, the largest online rental service for scholarly research with thousands of academic publications available at your fingertips. Thrombolytic therapy can thus be the first modality of treatment for acute nontraumatic upper limb ischaemia if the limb is viable. A dose of 600,000 iu urokinase was infused in 12 hours 50,000 iuhour. Gw26e2507 the effect of catheterdirected thrombolysis. Acute limb ischemia ali is defined as a sudden significant decrease in limb perfusion that has been present for less than 14days that is causing a threat to limb via. Lower limb thromboembolism can present in a number ofways.
1412 780 32 241 617 1381 694 380 989 1145 388 1147 1538 735 1275 953 678 21 644 1394 1575 1594 651 1035 339 34 661 905 579 431 972 1606 1422 133 50 1223 704 380 255 946 1329 1345 547 322 12 651 947 737